Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody

Giovanni Pacchiana(University of Turin), Elisa Vigna(Candiolo Cancer Institute)

Journal of Biological Chemistry

September 11, 2010

10.1074/jbc.m110.134031

Cited by 77

Related Papers

Dual Constant Domain‐Fab: A novel strategy to improve half‐life and potency of a Met therapeutic antibody

|Molecular Oncology|2016|14

A receptor-antibody hybrid hampering MET-driven metastatic spread

|Journal of Experimental & Clinical Cancer Research|2021|11

Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody

|Cancers|2020|3

Genetic Ablation of the MET Oncogene Defines a Crucial Role of the HGF/MET Axis in Cell-Autonomous Functions Driving Tumor Dissemination

|Cancers|2023|1